Foote Health System
Cancer Care Program
2006



Annual Oncology Report
Includes data collected through 2005

Foote Health System

University of Michigan Health System

Table of Contents

Report Focus: Bladder Cancer – Chairman's Report **3**

2005 Registry Data - Bladder Cancer **4**
Stage Distribution *4*
Age at Diagnosis *4*
First Course of Treatment *5*
Histology Distribution *5*

Taking Action Against Bladder Cancer **6**
Who is At Risk? *6*

2005 Registry Overview – All Cancers **7**
Primary Site Incidence Comparison *7*
Primary Site Table *8-9*

Cancer Care Program Committee Membership **10**

Foote Health System Programs and Services **11**

Important Phone Numbers **12**

Online Resources **13**

Compiled, November 2006

Report Focus: Bladder Cancer 2005

By: John Axelson, MD, Hematology & Oncology
Chairman, Cancer Committee

John Axelson, MD
Hematology & Oncology

Foote Health System
Cancer Committee Chairman

The five most prevalent cancer diagnoses within Foote Health System in 2005 were: lung, breast, prostate, colon, and bladder. Compared to national trends, Foote Hospital had a higher incidence of lung cancer diagnosis (5%) and a slightly lower incidence of breast cancer diagnosis (1%) than the national trends.

The focus of this year's report is bladder cancer, the fifth most common detected malignancy both at Foote Health System and nationally. The American Cancer Society (ACS) estimated 67,160 new bladder cancer diagnoses in 2007. Bladder cancer is 4 times more likely to be found in men. Statistically, a man has a 1 in 30 chance during his lifetime to develop bladder cancer; a woman is 1 and 90. At Foote Hospital, 44 patients had bladder cancer detected in 2005. There was a higher incidence of bladder cancer at Foote Health System than compared to national data for both the age groups in the fifth and eight decade. The good new is most of these cancers were caught early. At Foote Health System, 63% of the bladder cancer diagnosis were stage 0; compared to the national data at 53% stage 0. However, the incidence of stage 1 is 9 % below the national average of 20% and stage 2 is 10% higher than the national average 11%. Transurethral surgery (TURB) continues to be the standard treatment 83% at Foote Health System; compared to 66% nationally. We are increasingly dependent on NCCN web based guidelines. See **www.nccn.org**.

The Ray H. Clark Cancer Research Program of Foote Health System now participates in the Michigan Cancer Research Consortium Community Clinical Oncology Program (MCRC-CCOP), a NCI sponsored clinical trials program. Foote Health System is a component of a collaborative effort that includes 9 Michigan health care organizations which is one of 50 research programs established by NCI to provide patients access to national cancer research. Being participants of MCRC opens up to the Jackson community over 100 cooperative group Phase I, II, and III trials for both cancer prevention and treatment while patients remain in their own community. For more information on MCRC-CCOP trials available for each primary site, please visit **www.mcrconline.org**.

2005 Registry Data | *Bladder Cancer Statistics*

The Cancer Registry for the Cancer Care Program of Foote Health System is a data-collection system used to manage and analyze case data to provide a clear reading of the types and numbers of cases that occur in the Foote Health System service area. Data on new cancer cases each year is tracked and recorded according to malignancy. The data collected includes patient demographics, information concerning the tumor location, size, type and treatment. Patient identity is excluded from the database to protect patient confidentiality.









Taking Action Against Bladder Cancer

As far as screening tests, signs and symptoms, there is not much to report on for bladder cancer.

Who is At Risk?

Screening tests are not recommended unless you have strong risk factors: previous bladder cancer diagnosis, certain bladder defects, or exposure to certain chemicals.

Signs and symptoms of bladder cancer is blood in urine or changes in bladder habits. These signs may be caused by something other than cancer but they should not be ignored. Recommendation is to schedule an appointment with your physician to discuss what may be causing the symptoms.

Cancer Registry Overview

During 2005, a total of 801 new cancer cases were diagnosed as part of Foote Health System's Cancer Care Program. Of those cases, 687 were analytic cases, meaning the patients received all or part of their first course of treatment through Foote providers. Another 114 cases were non-analytic cases, meaning patients received their initial treatment elsewhere and were referred to Foote providers for subsequent treatment.



Foote Hospital's 20 05 Primary Site Table

PRIMARY SITE	TOTAL	PERC	SEX		CLASS	of CASE	ALIVE	EXP	AJCC STAGING/ANALYTICAL ONLY							
			M	F	Analyitcal	Non Analyitcal			0	1	2	3	4	*99	*88	*B/B
BRONCHUS AND LUNG	155	19.4	85	70	153	2	65	90	0	26	7	30	84	4	2	0
BREAST	150	18.7	4	146	141	9	142	8	32	47	36	20	4	1	1	0
PROSTATE GLAND	102	12.7	102	0	63	39	91	11	0	0	51	7	5	0	0	0
COLON	67	8.4	32	35	64	3	52	15	3	10	23	21	6	1	0	0
BLADDER	44	5.5	35	9	38	6	34	10	24	4	8	0	2	0	0	0
HEMATOPOIETIC/RETICULOEN	24	3	19	5	16	8	15	9	0	1	0	0	1	0	14	0
SKIN	23	2.9	11	12	11	12	20	3	3	5	1	0	2	0	0	0
CORPUS UTERI	22	2.7	0	22	14	8	21	1	0	8	1	1	1	2	1	0
LYMPH NODES	22	2.7	14	8	18	4	20	2	0	7	4	6	1	0	0	0
CERVIX UTERI	19	2.4	0	19	9	10	18	1	7	1	1	0	0	0	0	0
PANCREAS	16	2	9	7	15	1	3	13	0	3	7	2	3	0	0	0
KIDNEY	14	1.7	11	3	12	2	12	2	0	4	3	2	3	0	0	0
RECTUM	12	1.5	8	4	12	0	11	1	1	2	4	3	1	1	0	0
STOMACH	11	1.4	9	2	9	2	4	7	0	1	0	1	7	0	0	0
TESTIS	10	1.2	10	0	10	0	10	0	0	8	0	2	0	0	0	0
BRAIN	9	1.1	6	3	9	0	8	1	0	0	1	0	0	0	8	0
THYROID GLAND	7	0.9	4	3	7	0	4	3	0	1	1	1	4	0	0	0
TONSIL	6	0.7	5	1	6	0	6	0	0	0	0	0	6	0	0	0
ESOPHAGUS	6	0.7	3	3	6	0	1	5	0	2	0	1	3	0	0	0
CONN, SUBQ AND OTH SOFT	6	0.7	3	3	5	1	5	1	0	1	1	1	1	1	0	0
OVARY	6	0.7	0	6	6	0	5	1	0	2	0	0	3	1	0	0
UNKNOWN PRIMARY SITE	6	0.7	1	5	6	0	3	3	0	0	0	0	0	0	6	0
ANUS AND ANAL CANAL	5	0.6	1	4	5	0	5	0	0	0	2	2	0	1	0	0
LARYNX	5	0.6	4	1	5	0	5	0	0	3	0	1	1	0	0	0
SMALL INTESTINE	4	0.5	3	1	4	0	3	1	0	0	0	0	0	1	3	0
RECTOSIGMOID JCT	4	0.5	3	1	4	0	3	1	1	0	2	0	0	1	0	0
LIVER-INTRAHEP BILE DUCTS	4	0.5	3	1	4	0	1	3	0	1	0	0	3	0	0	0
VULVA	4	0.5	0	4	1	3	3	1	0	0	1	0	0	0	0	0
PENIS	3	0.4	3	0	2	1	3	0	0	2	0	0	0	0	0	0
RENAL PELVIS	3	0.4	2	1	3	0	2	1	0	1	2	0	0	0	0	0
EYE AND ADNEXA	3	0.4	2	1	3	0	1	2	0	1	0	0	1	0	1	0
BASE OF TONGUE	2	0.2	2	0	2	0	2	0	0	0	0	0	1	1	0	0
FLOOR OF MOUTH	2	0.2	2	0	2	0	1	1	0	1	0	0	1	0	0	0
OROPHARYNX	2	0.2	1	1	2	0	2	0	0	0	1	0	0	1	0	0
NASOPHARYNX	2	0.2	2	0	1	1	2	0	0	1	0	0	0	0	0	0
OTH & UNSPEC PTS OF BILE DUCT	2	0.2	0	2	2	0	0	2	0	0	1	0	0	1	0	0
HEART, MEDIASTINUM AND P	2	0.2	1	1	2	0	0	2	0	1	0	0	1	0	0	0
BONES, JNTS, ART CART LIGAMENTS	2	0.2	2	0	2	0	2	0	0	0	0	0	0	0	2	0
MENINGES	2	0.2	1	1	2	0	2	0	0	0	0	0	0	0	0	2
LIP	1	0.1	1	0	1	0	1	0	0	1	0	0	0	0	0	0
OTH & UNSPEC PARTS OF TONGUE	1	0.1	0	1	1	0	1	0	0	1	0	0	0	0	0	0
GUM	1	0.1	1	0	0	1	1	0	0	0	0	0	0	0	0	0
OTH PARTS OF MOUTH	1	0.1	1	0	1	0	1	0	0	1	0	0	0	0	0	0
PAROTID GLAND	1	0.1	0	1	1	0	1	0	0	0	1	0	0	0	0	0
OTH PARTS MAJ SALIVARY GLAND	1	0.1	0	1	1	0	1	0	0	1	0	0	0	0	0	0
HYPOPHARYNX	1	0.1	0	1	1	0	0	1	0	0	1	0	0	0	0	0
NASAL CAV/MIDDLE EAR	1	0.1	0	1	1	0	1	0	0	1	0	0	0	0	0	0
THYMUS	1	0.1	1	0	1	0	1	0	0	0	0	0	0	0	1	0
RETROPERITONEUM AND PERI	1	0.1	1	0	1	0	0	1	0	0	1	0	0	0	0	0
UTERUS, NOS	1	0.1	0	1	1	0	1	0	1	0	0	0	0	0	0	0
URETER	1	0.1	0	1	1	0	0	1	0	0	1	0	0	0	0	0
OTHER CNS SYSTEM	1	0.1	0	1	0	1	1	0	0	0	0	0	0	0	0	1
TOTAL	**801**	**100**	**408**	**393**	**687**	**114**	**597**	**204**	**72**	**149**	**162**	**101**	**145**	**17**	**39**	**3**

Key:

*88=AJCC Staging doesn't apply

*99=Unstageable

*B/B=Benign Brain/CNS

Cancer Care Programs and Services

Cancer Committee

Resources of the Cancer Care Program at Foote Health System stay on the leading edge due to the effective leadership of its Cancer Committee. This group of oncologists and other cancer specialists direct the quality standards of the program, including continuing staff education and accreditation requirements. The combined efforts and talents of these professionals provide an opportunity to share expertise on cancer treatments and initiatives and to incorporate new technology into treatment planning.

The committee is comprised of:

Physician Members 2005

John Axelson MD, Hematology & Oncology

Richard V. A. Dieterele, MD,
Director, Pathology

David Eggert, MD

Michael Sheth, MD, Pain Management

Molly Sullivan, MD, Radiation Oncologist

Anil Tibrewal MD, General Surgeon

David Williamson, MD, Radiology

Additional Members 2005

Deborah Dusseau, BS, RT,
Manager, Radiation Oncology

Dawn Brannick, RN, Wellness Education

Susan Caines, BSN, MBA Quality Management

Jill Drewno, RN, OP IV Services

Joan Ezinga, RN, Passages

Mary Floros, CTR, RHIT, Cancer Registrar

Nyoshini Govender, RBScPT,
Manager, Outreach Services

Terrance Keys, Administrator, Imaging Services, Radiation Oncology, Cardio-pulmonary diagnostics, Foote Diagnostic Center, Patient Scheduling

Robin Kirkpatrick,
Director, Marketing

Lil McGaffigan, BSN, RN Case Management

Carrie Tallman, RN,
Clinical Trial Coordinator

Rachel Wheeler, RN, Nurse Manager
Medical Oncology Unit

Cancer Research

Hematology and Oncology Associates, along with Foote Health System, jointly operate the Ray H. Clark Cancer Research Program and maintain an affiliation with the University of Michigan Cancer Care Network. This relationship allows our patients direct access to clinical trial protocols (cancer research) available through the National Cancer Institute.

Supporting Programs and Services

- Case Management
- Cancer Conference
- Center for Pain Management
- Home Care Services
- Hospice of Jackson
- Imaging Services
- Inpatient Hospice Care
- Inpatient Oncology
- Outpatient Chemotherapy
- Outpatient IV Services
- Pastoral Care
- Pharmacy
- Radiation Oncology
- Registered Dietitians
- Rehabilitation Services

Local Support Groups

- Living Stronger Together (chronic illnesses)
- RENEW (breast/gynecological cancer)
- Man to Man (prostate cancer)

Directory Important Phone Numbers

Medical Oncologists

Hematology and Oncology Associates	789-7122
Central Clinic, P.C.	787-8371

Radiation Oncologists

Paul Tejada Center for Radiation Oncology	780-7299

Access Center (24-hours crisis counseling line)	789-5971
Case Management Department	788-4950
Center for Pain Management	788-4841
Foote Home Care Services	841-6984
Hospice of Jackson	841-6983
Ray H. Clark Cancer Research Program	841-1413
Support Group Information	780-7299
Outpatient IV Services	788-4922
Pastoral Care	788-4889
Patient Representative	788-4740
Pharmacy	788-4817
Registered Dietitians	787-3806
Rehabilitation Services	
Inpatient	788-4704
Outpatient	788-4856

Online resources

National Comprehensive Cancer Network	**www.nccn.com**
American Cancer Society	**www.cancer.org**
National Cancer Institute	**1-800-4CANCER** **www.cancer.gov**
Center for Disease Control	**www.cdc.gov/cancer/screenforlife**
Foote Health System	**www.footehealth.org**
Michigan Cancer Research Consortium	**www.mcrconline.org**
To determine Medicare coverage	**1-800-MEDICARE**
People Living with Cancer	**www.plwc.org**



Cancer Care Program

Foote Health System

205 N. East Avenue
Jackson, MI 49201

517-780-7280